Contact
Please use this form to send email to PR contact of this press release:
Exicure, Inc. (Nasdaq: XCUR) Nears Completion of Phase 2 Study of GPC-100 in Multiple Myeloma
TO:
Please use this form to send email to PR contact of this press release:
Exicure, Inc. (Nasdaq: XCUR) Nears Completion of Phase 2 Study of GPC-100 in Multiple Myeloma
TO: